N. G. R. Dayan Elshan

Dr. N. G. R. Dayan Elshan

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2018 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
NEN. G. R. Dayan Elshan
N. G. R. Dayan Elshan
MRMatthew B. Rettig
Matthew B. Rettig
MJMichael E. Jung
Michael E. Jung

9 February 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
NEN. G. R. Dayan Elshan
N. G. R. Dayan Elshan
KWKaren C. Wolff
Karen C. Wolff
LRLaura Riva
Laura Riva
AWAshley K. Woods
Ashley K. Woods
GGGennadii Grabovyi
Gennadii Grabovyi
ACArnab K. Chatterjee
Arnab K. Chatterjee
There remains a need to develop novel SARS-CoV-2 therapeutic options that improve upon existing therapies by an increased robustness of response, fewer safety liabilities, and global-ready accessibility. Functionally critical viral main protease (Mpro, 3CLpro) of SARS-CoV-2 is an attractive target due to its homology within the coronaviral family, and lack thereof toward human proteases. In this disclosure, we outline the advent of a novel SARS-CoV-2 3CLpro inhibitor, CMX990, bearing an unprecedented trifluoromethoxymethyl ketone warhead. Compared with the marketed drug nirmatrelvir (combination with ritonavir = Paxlovid), CMX990 has distinctly differentiated potency (∼5× more potent in primary cells) and human in vitro clearance (>4× better microsomal clearance and >10× better hepatocyte clearance), with good in vitro-to-in vivo correlation. Based on its compelling preclinical profile and projected once or twice a day dosing supporting unboosted oral therapy in humans, CMX990 advanced to a Phase 1 clinical trial as an oral drug candidate for SARS-CoV-2.

1 November 2014 in Analytical Biochemistry
Verified
Journal Article
Closed access
NEN. G. R. Dayan Elshan
N. G. R. Dayan Elshan
RPRenata Patek
Renata Patek
JVJosef Vagner
Josef Vagner
EMEugene A. Mash
Eugene A. Mash

3 December 2014 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
NEN. G. R. Dayan Elshan
N. G. R. Dayan Elshan
TJThanuja Jayasundera
Thanuja Jayasundera
BABobbi L. Anglin
Bobbi L. Anglin
CWCraig S. Weber
Craig S. Weber
RLRonald M. Lynch
Ronald M. Lynch
EMEugene A. Mash
Eugene A. Mash
Short, efficient syntheses of multivalent molecules targeted to the human melanocortin 4 receptor based on phloroglucinol, tripropargylamine, and 1,4,7-triazacyclononane are described.

1 September 2013 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
RARamesh Alleti
Ramesh Alleti
JVJosef Vagner
Josef Vagner
DDDilani Chathurika Dehigaspitiya
Dilani Chathurika Dehigaspitiya
VMValerie E. Moberg
Valerie E. Moberg
NEN. G. R. Dayan Elshan
N. G. R. Dayan Elshan
EMEugene A. Mash
Eugene A. Mash

13 May 2019 in Organic Letters
Verified
Journal Article
Closed access
NEN. G. R. Dayan Elshan
N. G. R. Dayan Elshan
MRMatthew B. Rettig
Matthew B. Rettig
MJMichael E. Jung
Michael E. Jung